diffuse large B cell lymphoma
Conditions
Interventions
TP53 mutated de novo diffuse large B cell lymphoma:ARCHOP
Sponsors
the First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1)Age between 18 to 70 years old (including 18 and 70); 2)Confirmed treatment-naïve TP53 mutated de novo diffuse large B cell lymphoma, Immunohistochemistry showed that TP53 was not expressed or exceeded 50%; 3)ECOG score 0-2; 4)cardiac ejection fraction of >45%; 5)HBV negative or HBV positive patient required to have HBV DNA<1.0×10^3 IU/ml before entering the group; 6)Adequate organ function ( serum bilirubin = 2x ULN, AST or ALT= 2.5 x ULN, and CRE= 2 x ULN unless due to lymphoma with documentation of normal function prior to onset of lymphoma; 7)Life expectancy no less than 6 months; 8)Able to give informed consent
Exclusion criteria
Exclusion criteria: 1)Symptomatic CNS lymphoma involvement; 2)Known HIV infection or HCV Active infection(HCV DNA positive); 3) Clinically symptomatic secondary cardiovascular diseases such as uncontrolled hypertension (resting diastolic blood pressure > 115 mmHg), uncontrolled arrhythmias, symptomatic angina, or NYHA CLASS III-IV congestive heart failure; 4)severe chronic obstructive pulmonary disease with hypoxemia; 5)Uncontrollable systemic infection(Bacteria, fungi and/or viruses); 6)Past or present co-existing malignancies (other than non-melanoma basal cell carcinoma of the skin, carcinoma in situ of the breast/cervix, and other malignancies that have been effectively controlled without treatment in the past three years); 7)Hypersensitivity or allergic reactions to murine antibodies or proteins
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival; | — |
Countries
China
Contacts
Public Contactbing xu
The First Affiliated Hospital of Xiamen University
Outcome results
None listed